Recent trial data have expanded the use of neoadjuvant and adjuvant immunotherapy in locally advanced head and neck cancer. The data outline potential benefits in high-risk, HPV-negative disease, while also introducing important considerations around treatment sequencing, toxicity, and patient selection. Understanding these findings is critical for translating emerging evidence into everyday clinical practice.
Contributors:
Dr. Jennifer Johnson is a head and neck surgeon and Associate Professor in the Departments of Medical Oncology and Otolaryngology at Thomas Jefferson University in Philadelphia, Pennsylvania.
Dr. Adam Luginbuhl is an Associate Professor of Otolaryngology Head and Neck Surgery at Thomas Jefferson University.
Dr. Mihir Patel is a head and neck surgical oncologist and professor at UNC School of Medicine and Lineberger Comprehensive Cancer Center.
Dr. Siddharth Sheth is a head and neck medical oncologist at UNC School of Medicine in Chapel Hill, North Carolina.
